CompoAtlas

Copaltra

Food supplement declared in France, declaration No 2024-1-1537, decision dated 30 January 2024

Copaltra (IPHYM) is a food supplement declared in France. Status: declared in France, may be marketed. None of the rules we check flags an issue with its declared composition.

Brand
IPHYM
Food business operator placing the product on the market
Laboratoires IPHYM
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Capsule
Daily dose
4 gélules par jour
Directions for use
2 gélules ¼ d’heure avant les repas du midi et du soir
Intended populations
People over 60, Men, Women
Not recommended (according to the manufacturer)
Adolescents (under 18), Breastfeeding women, Pregnant women, Kidney disease, Heart problems
Objectives stated by the manufacturer (these are not authorised claims)
Slimming / Blood sugar

Declaration 138664, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Olea europaea subsp. europaeaFeuilleExtrait sec alcoolique720 mg
Vaccinium myrtillus L.FeuillePoudre (de plantes séchées ou broyées)400 mg

Additives

Hydroxypropyl Méthyl Cellulose

Other ingredients

maltodextrine

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Photograph the packaging

Label warnings

Produit destiné à l'adulte. Déconseillé chez l’enfant et l’adolescent, la femme enceinte et allaitante et en cas d’insuffisance cardiaque ou rénale. Ne pas dépasser la dose journalière recommandée. Ne se substitue pas à un régime alimentaire varié et sera utilisé dans le cadre d’un mode de vie sain. Ne pas laisser à la portée des jeunes enfants.

Regulatory points

None of the rules we check applies to the declared ingredients.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Olea europaea subsp. europaea
    Read the warning, when it applies and the studies cited

    OLIVE LEAF - OLEA EUROPAEA

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you pregnant or breastfeeding (EMA 2017).

    Sources cited by Health Canada (1)
    • EMA 2017: European Medicines Agency. European Union herbal monograph on Olea europaea L., folium. [Accessed 2024 November 27]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-olea-europaea-l-folium-first-version_en.pdf

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a kidney disorder (EMA 2017).

    Sources cited by Health Canada (1)
    • EMA 2017: European Medicines Agency. European Union herbal monograph on Olea europaea L., folium. [Accessed 2024 November 27]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-olea-europaea-l-folium-first-version_en.pdf

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking other diuretics (EMA 2017).

    Sources cited by Health Canada (1)
    • EMA 2017: European Medicines Agency. European Union herbal monograph on Olea europaea L., folium. [Accessed 2024 November 27]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-olea-europaea-l-folium-first-version_en.pdf

    Known adverse reactions

    Condition of application: All products except those making a diuretic claim.

    When using this product diuretic effect may occur.

    Health Canada monograph dated 19 December 2025

  • Vaccinium myrtillus L.
    Read the warning, when it applies and the studies cited

    BILBERRY - VACCINIUM MYRTILLUS - Buccal

    Route of administration: Buccal (Blumenthal et al. 2000)

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 30 January 2026

    BILBERRY - VACCINIUM MYRTILLUS - Oral

    Route of administration: Oral (Blumenthal et al. 2000)

    Cautions and warnings

    Condition of application: Relief of diarrhea.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: Slowing the progression of disorders of the eye and to relieve symptoms related to non-complicated CVI.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.

    Health Canada monograph dated 25 October 2024

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Other declarations with the same name

In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.

Brand : IPHYM

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

List recorded in 2024. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line